Avertissement: Ce site agrège des données publiques officielles provenant de la FDA, ClinicalTrials.gov, PubMed et SEC EDGAR à titre de référence générale uniquement. Il ne constitue pas un avis médical, un diagnostic, une recommandation de traitement ni un conseil en investissement.

PubMed

Unravelling the Immunotoxicity of Polycaprolactone Nanoparticles-Effects of Polymer Molecular Weight, Hydrolysis, and Blends.

PMID : 33050694 ·

S, a, n, d, r, a, , J, e, s, u, s, ;, , N, a, t, a, l, i, a, , B, e, r, n, a, r, d, i, ;, , J, e, s, s, i, c, a, , d, a, , S, i, l, v, a, ;, , M, a, r, i, a, n, a, , C, o, l, a, ç, o, ;, , J, o, ã, o, , P, a, n, ã, o, , C, o, s, t, a, ;, , P, e, d, r, o, , F, o, n, t, e, ;, , O, l, g, a, , B, o, r, g, e, s

RevueChemical research in toxicology
Année
PMID33050694

Résumé

Poly-ε-caprolactone (PCL) is a biodegradable polyester that has FDA and CE approval as a medical device. Nonetheless, the lack of toxicity exhibited by the polymer cannot be extrapolated to its nanomaterial conformation. Despite PCL-based NPs being widely studied in the biomedical field for their advantages as controlled drug delivery systems, little data describe PCL NPs' toxicity, particularly immunotoxicity. This work assessed different PCL-based delivery systems intended for protein delivery

Source officielle

Voir sur PubMed →

Données issues de PubMed / NCBI. Pour le texte intégral et les informations les plus récentes, consultez toujours la notice officielle.

↑